Novo Nordisks Aleksandar Ciric writes that leaders can apply sports principles such as speed of action, clarity, and ...

Speed to market wont guarantee success in todays launch environment. Anticipating what prescribers, patients and payers will ...

Royalty-bearing license agreements are a cornerstone of commercialization in the life sciences and technology industries. Companies often use them to expand their business into new markets while ...

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...

Recently, there has been heightened focus on dual brand approaches in which the same molecule is approved for multiple indications and packaged, priced, and distributed under different brand names.

“THAT WAS A TERRIFYING MOMENT,” reflects Matt Patterson, cofounder, chairman, and CEO of Audentes Therapeutics, a genetic medicines company focused on the adeno-associated virus (AAV). It was the fall ...

In the rapidly evolving world of life sciences, companies are constantly seeking ways to optimize their business structures to better navigate the complex landscape of drug development and financing.

Amid recent and proposed sweeping cuts to federal research funding, ranging from suspended federal funding to universities and research facilities to updated policy by the NIH (NIH) to reduce indirect ...

Why did John Oyler, an American entrepreneur, decide to build a global biopharmaceutical company with roots in China? Ask the chairman, cofounder, and CEO of BeiGene that question and you’re going to ...

New York City-based Volastra Therapeutics – whose founders and scientific advisors are leading chromosomal instability researchers and experts – have in four years’ time advanced two drug candidates ...

The False Claims Act (FCA) and the Anti-Kickback Statute (AKS) are two of the Department of Justice’s (DOJ) primary tools when it comes to fighting fraud. Originally enacted during the Civil War to ...

For Boehringer Ingelheim’s (BI) first foray into biosimilars, the company went straight to the top, developing an interchangeable biosimilar for AbbVie’s Humira, one of the best-selling pharmaceutical ...